Trametinib, a mitogen-activated protein kinase (MEK) inhibitor targeting MEK1 and MEK2, crucial components of the MAPK/ERK pathway, has emerged as a potential treatment of NF1 altered cancers (5, 6). This evidence concerns the gene NF1 and cancer.